Evidence map›Paper›PMID 30590191›Full record

Observational studyHeart rhythm2019

Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study.

Quynh A Truong, Jackie Szymonifka, James L Januzzi, Jigar H Contractor, Roderick C Deaño, Neal A Chatterjee, Jagmeet P Singh

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Heart rhythm, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. New aspects in cardiorenal syndrome and HFpEF.Clinical kidney journal · 2022
    Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Quynh A TruongDepartment of Radiology and Medicine, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, New York; Department of Biostatistics, New York University, New York, New York. Electronic address: qat9001@med.cornell.edu.
Jackie SzymonifkaDepartment of Biostatistics, New York University, New York, New York.
James L JanuzziDivision of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Jigar H ContractorDepartment of Medicine, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, New York.
Roderick C DeañoDepartment of Medicine, Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Neal A ChatterjeeDivision of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Jagmeet P SinghDivision of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Harvard University · USCornell University · USMassachusetts General Hospital · USNew York University · USUniversity of Wisconsin–Madison · USWeill Cornell Medicine · US

Funding

Computed Tomography to Predict Response to Cardiac Resynchronization TherapyK23HL098370 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI TRUONG, QUYNH A. · 2010 to 2014
$816k
NHLBI NIH HHS K23 HL098370
6 · The paper itself

Abstract

backgroundCardiorenal syndrome comprises a heterogeneous group of disorders characterized by acute or chronic cardiac and renal dysfunction.

objectiveThe purpose of this study was to determine the effect of cardiorenal status using a dual-marker strategy with amino-terminal pro-brain natriuretic peptide (NT-proBNP) and cystatin C on cardiac resynchronization therapy (CRT) outcomes.

methodsIn 92 patients (age 66 ± 13 years; 80% male; left ventricular ejection fraction 26% ± 7%), NT-proBNP and cystatin C levels were measured at CRT implantation and at 1 month. NT-proBNP >1000 pg/mL and cystatin C >1 mg/L were considered high. Baseline cardiorenal patients were defined as having high NT-proBNP and cystatin C. At 1 month, CRT patients were categorized as (1) irreversible cardiorenal if cystatin C was persistently high; (2) progressive cardiorenal with transition from low to high cystatin C; (3) reversible cardiorenal with transition from high to low cystatin C; and (4) "normal" with stable low cystatin C. Outcomes were 6-month clinical and echocardiographic CRT response and 2 -year major adverse cardiovascular event (MACE).

resultsCompared to patients with low NT-proBNP and cystatin C, cardiorenal patients had >9-fold increase risk of CRT nonresponse (odds ratio uncompensated 9.0; compensated 36.4; both P ≤.004) and >6-fold risk of MACE (hazard ratio uncompensated 8.5; P = .005). Compared to "normal" and reversible patients (referent), irreversible patients had a 9-fold increase for CRT nonresponse (odds ratio 9.1; P <.001) and had >4-fold risk of MACE (adjusted hazard ratio 5.1; P <.001). Irreversible patients were most likely echocardiographic CRT nonresponders.

conclusionCardiorenal status by NT-proBNP and cystatin C can identify high-risk CRT patients, and those with both elevated concentrations have worse prognosis.

Indexed as

Cardiac Resynchronization TherapyCardio-Renal SyndromeHeart FailureAgedBiomarkersCystatin CEchocardiographyFemaleHumansKidney Function TestsMaleNatriuretic Peptide, BrainPeptide FragmentsPrognosisRisk AssessmentStroke VolumeBiomarkersCystatin CNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)BiomarkersCardiac resynchronization therapyHeart failureNatriuretic peptideRenal function

Identifiers

PMID30590191
PMCPMC6545247
OpenAlexW2905826830

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.